Leo Rasche
@RascheLeo
Followers
367
Following
465
Media
1
Statuses
105
Joined October 2022
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study @BloodCancerJnl
https://t.co/0aZ48Gf33B
nature.com
Blood Cancer Journal - Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
1
9
25
CIDP as another (rare) MNT-style AE of cilta-cel in #MMsm. Great correlatives in @BloodCancerJnl by 🇩🇪 group: TCRseq identified oligoclonal CARs (CDR epitopes similar to GBS) in one case. Early treatment with high-dose Cy, IT chemo is key - now need preemptive ID & mitigation!
Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy @BloodCancerJnl
https://t.co/B4gnx0tfNx
0
5
17
The NDMM prognostic score from the IMS is out. How should we deal with it in daily practice, across laboratories with different expertises and resources? Within the European Myeloma Network we discuss this issue @Hemasphere_EHA #mmsm #MultipleMyeloma #RRMM
https://t.co/K1ceTSgTat
onlinelibrary.wiley.com
Given the evolving understanding of genetic risk factors in multiple myeloma (MM), this paper assesses whether next-generation sequencing (NGS) could complement or even replace fluorescence in situ...
1
10
16
#OnlineFirst Timing Genomic Antigen Loss in #MultipleMyeloma Treated with T Cell–Redirecting Immunotherapies https://t.co/RBGZzjG1Gu
0
4
2
Fascinated by the emerging field of spatial transcriptomics in the bone marrow. Happy to share our new editorial, co-authored with Niels Weinhold: Unlocking myeloma’s spatial world at the micrometer scale. https://t.co/UF3AEcjWjT I also recommend the new paper by Yip et al. 👍
0
5
21
Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14
8
37
89
Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia https://t.co/jaHAdJ5yjH
0
6
19
And now @MeeraMohanMD tried to address the question of many’s minds: what happens when bispecific antibodies are stopped in patients with deep response? N=78 97% in vgpr or better 72% BCMA bsab Most common reason for stopping was infection. 24 months relapse free survival 68%.
0
17
41
Updates from MajesTEC-5: Continue to see unprecedented mrd negativity rates after just 6 cycles of teclistamab + Dara-R and +\- bortezomib. Pretty clear that bortezomib thus far not offering benefit. Is transplant really needed either? Infection rates a bit concerning with short
3
16
49
1/ If validated & correct pts identified, will be practice-changing 👏 We know tumor burden ⬇️ ORR with BCMA bsAbs in #MMsm. in 🇩🇪 @LeukemiaJnl paper, PACE ⬇️ sBCMA and tec started working. Provocative ❓: Can plasmapheresis alongside chemo (or GSI??) expedite sBCMA clearance?
#Myeloma Paper of the Day: Plasmapheresis may facilitate soluble BCMA clearance & contribute to reversing primary resistance to anti-BCMA immunotherapy in myeloma (based on 1 patient who also got D-P(A)CE + pre-clinical studies): https://t.co/3df1FVmoFS.
#mmsm Conclusion .
1
9
22
Excited to share new @BCD_AACR paper where we show how BCMA mutations driving BsAb resistance are acquired during therapy. Another exciting study from our great collaboration with Paola Neri @NBahlis @RascheLeo! @MSKCancerCenter @MSK_DeptOfMed @SylvesterCancer @UCalgary #mmsm
2
6
29
A new contribution from MRC myeloma XI showing that with good diagnostic testing functional high risk is very rare @MyMKaiser
4
4
15
Excited to share our new paper, out today on @NatureGenet where we use 421 #WGS to reconstruct the evolutionary history of multiple myeloma #mmsm (🔥🔥). Great collaboration with @HDMyeloma @SylvesterCancer @MayoClinic @MSKCancerCenter @MSK_DeptOfMed .
17
38
136
#Myeloma Paper of the Day: Clonal hematopoiesis + elevated ferritin highly predictive of prolonged cytopenias in BCMA CAR T treated pts; 9% developed secondary myeloid diseases including high grade MDS associated w/ expansion of TP53-mutated clones: https://t.co/Y533iRU41Z.
#mmsm
3
18
44
Compared to teclistamab and talquetamab, both Ide-cel and cilta-cel were associated with higher response rates, deeper responses, and longer PFS in RRMM with EMD #mmsm #bmtsm @MJSteinhardt @RascheLeo @BloodCancerJnl
nature.com
Blood Cancer Journal - Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
1
8
21
The MonumenTAL-1 trial confirms talquetamab's efficacy and safety in treating relapsed/refractory multiple myeloma. Despite high-risk factors, a 65% response rate and 6.4 months median progression-free survival were observed. These findings support use in advanced stages.
0
4
16
🧬 Proud to share: Publication in Blood Cancer Journal: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with EMD 👉CAR T-cell therapy and effective debulking resulted in higher EMD response rates, and prolonged PFS 👉
0
2
8
Check our recent work @UAMSMyeloma published @BloodAdvances : Prognostic Impact of Focal Lesion Location and Persistence in Multiple Myeloma: Insights from Serial PET/DWI Imaging #mmsm ➡️ https://t.co/O2RQaZ4ZNH n= 243 multiple myeloma patients followed 9.9 years with serial
0
12
29
Excellently written @NatureMedicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPMs) that I’ve ever seen 👏 these will be used in slide decks everywhere! Congrats @KRejeski @JoshuaHillMD @MichaelDJain and thanks for writing this! #MMsm #lymsm
🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 https://t.co/uNcE2mBNUi PDF:
2
42
121